Table I.
Characteristics of patients screened (March 2005-February 2008).
| Total | Total | Enrolled | Ineligible | Eligible but not enrolled, by site or patient choice | |
|---|---|---|---|---|---|
|
|
|
|
|
||
| No. (Col %) 7452 | No. (Row %) 3868 (51.9) | No. (Row %) 1469 (19.7) | No. (Row %) 2115 (28.4) | OR (95% Cl) − (−) | |
|
| |||||
| Sex | |||||
| Male | 4046 (54.3) | 2119(52.4) | 791 (19.6) | 1 136 (28.1) | 1.0 (−) |
| Female | 3406 (45.7) | 1749 (51.4) | 678 (19.9) | 979 (28.7) | 1.04 (0.94–1.16) |
| Age group (years)a | |||||
| 2–17 | 757 (10.2) | 480 (63.4) | 101 (13.3) | 176 (23.2) | 1.0 (−) |
| 18–35 | 2878 (38.6) | 1567 (54.4) | 492 (17.1) | 819 (28.5) | 1.43 ( 1.18–1.73)b |
| ≥36 | 3816 (51.2) | 1821 (47.7) | 876 (23.0) | 1 1 19 (29.3) | 1.68 ( 1.39–2.02)b |
| Unknown | 1 (0) | – (−) | – (−) | 1 (100) | – (−) |
| Birthplacec | |||||
| Canada and United States | 2368 (31.8) | 1391 (58.7) | 383 (16.2) | 594 (25.1) | 1.0 (−) |
| Africa | 261 (3.5) | 104 (39.8) | 50 (19.2) | 107 (41.0) | 2.41 ( 1.81–3.21 )b |
| Americas—other | 2824 (37.9) | 1758 (62.3) | 358 (12.7) | 708 (25.1) | 0.94 (0.83–1.07) |
| Eastern Mediterranean | 153 (2.1) | 66 (43.1) | 27 (17.6) | 60 (39.2) | 2.13 ( 1.48–3.06)b |
| Europe | 282 (3.8) | 151 (53.5) | 56 (19.9) | 75 (26.6) | 1.16 (0.87–1.56) |
| South-East Asia | 207 (2.8) | 92 (44.4) | 41 (19.8) | 74 (35.7) | 1.88 ( 1.37–2.6)b |
| Western Pacific | 1008 (13.5) | 303 (30.1) | 418 (41.5) | 287 (28.5) | 2.22 (l.84–2.68)b |
| Non-WHO region | 3 (0) | 2 (66.7) | – (−) | 1 (33.3) | – (−) |
| Unknown | 346 (4.6) | 1 (0.3) | 136 (39.3) | 209 (60.4) | – (−) |
| Screening countryd | |||||
| United States | 6211 (83.3) | 3164 (50.9) | 1324 (21.3) | 1723 (27.7) | 1.0 (−) |
| Brazil | 546 (7.3) | 403 (73.8) | 24 (4.4) | 1 19 (21.8) | 0.54 (0.44–0.67)b |
| Canada | 420 (5.6) | 119 (28.3) | 87 (20.7) | 214 (51.0) | 3.30 (2.62–4.16)b |
| Spain | 275 (3.7) | 182 (66.2) | 34 (12.4) | 59 (21.5) | 0.60 (0.44–0.8)b |
| Racee | |||||
| White | 3938 (52.8) | 2418 (61.4) | 545 (13.8) | 975 (24.8) | 1.0 (−) |
| American Indian/Alaska Native | 33 (0.4) | 14 (42.4) | 6 (18.2) | 13 (39.4) | 2.30 ( 1.08–4.92)b |
| Asian/Pacific Islander | 1357 (18.2) | 443 (32.6) | 503 (37.1) | 411 (30.3) | 2.30 (l.97–2.68)b |
| Black | 1660 (22.3) | 878 (52.9) | 280 (16.9) | 502 (30.2) | 1.42 (1.24–l.62)b |
| Other | 124 (1.7) | 98 (79.0) | 14 (11.3) | 12 (9.7) | – (−) |
| Unknown | 340 (4.6) | 17 (5.0) | 121 (35.6) | 202 (59.4) | – (−) |
| Ethnicityf | |||||
| Hispanic | 2732 (36.7) | 1648 (60.3) | 368 (13.5) | 716 (26.2) | 1.0 (−) |
| Non-Hispanic | 3602 (48.3) | 1635 (45.4) | 930 (25.8) | 1037 (28.8) | 1.46 (1.3-1.64)b |
| Non-US/Canadian | 821 (11.0) | 585 (71.3) | 58 (7.1) | – | –(−) |
| Unknown | 297 (4.0) | –(−) | 113 (38.0) | 184 (62.0) | –(−) |
| Indications for LTBI treatmentg | |||||
| Contact | 4717 (63.3) | 2602 (55.2) | 710 (15.1) | 1405 (29.8) | 1.0 (−) |
| Contact and TST converter | 342 (4.6) | 239 (69.9) | 29 (8.5) | 74 (21.6) | 0.57 (0.44–0.75)b |
| TST converter | 1861 (25.0) | 855 (45.9) | 458 (24.6) | 548 (29.4) | 1.19 (1.05–1.35)b |
| Fibrosis | 333 (4.5) | 74 (22.2) | 206 (61.9) | 53 (15.9) | 1.33 (0.93–1.9) |
| HIV-positive | 150 (2.0) | 80 (53.3) | 42 (28.0) | 28(18.7) | 0.65 (0.42–1.0) |
Birthplace: Americas-other (Americas, not Canada or the United States); Cl: confidence interval; fibrosis: fibrosis on chest radiograph; HIV: human immunodeficiency virus; LTBI: latent tuberculosis infection; LTBI treatment indications—contact: contact with infectious tuberculosis case; contact and TST converter: contact with infectious tuberculosis case and TST converter; OR: odds ratio; TST: tuberculin skin test; WHO: World Health Organization.
Age group: “Unknown” (total, n = I; not enrolled, n = I): among those not enrolled and not included in univariate analysis.
Logistic regression and Wald chi-square tests were used to generate ORs and 95% CIs, compared not enrolled categories with enrolled. All overall P-values (not shown) for variables were significant except for “Sex: Total”; significant variable categories are indicated with footnoteb.
Birthplace: “Non-WHO Region” (total, n = 3; not enrolled, n = I) and “Unknown” include not reported (total, n = 346; not enrolled, n = 345): not included in univariate analysis.
Screening country: one site only in Canada enrolled (n = 6) and did not provide information about patients who were screened but not enrolled.
Race: “Other” includes multiracial (total, n = 124, not enrolled, n = 26), and “Unknown” includes not reported (total, n = 340; not enrolled, n = 323): not included in univariate analysis.
Ethnicity: for the main PREVENT TB (Sterling et al.3), ethnicity was evaluated only among patients screened in the United States and Canada. “Unknown” includes not reported (total, n = 297; not enrolled, n = 297): not included in univariate analysis.
indications for LTBI treatment: participants who had other combinations of risk factors (n = 49), not shown because of limited numbers.